AIR Industries Group — Q1 2023 Form 10-Q
Business context and period. The filing covers the three months ended March 31, 2023, with comparison to Q1 2022. AIR Industries manufactures aerospace components and assemblies, primarily for defense customers, through its subsidiaries.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Net sales | $12.549 million | $12.062 million; up 4.0% |
| Gross profit / margin | $1.880 million / 15.0% | $2.078 million / 17.2% |
| Operating income (loss) | ($158,000) | $207,000 |
| Net loss | ($618,000), or ($0.19) per diluted share | ($28,000), or ($0.01) per diluted share |
| Operating cash flow | $1.438 million | $1.285 million |
| Capital expenditures | $973,000 | $430,000 |
| Cash at period end | $1.125 million | $281,000 at Dec. 31, 2022 |
Operating expenses rose 8.9% to $2.038 million, mainly from professional fees and information technology costs. Interest and financing costs increased 47.4% to $476,000; the average interest rate was 7.04%, versus 3.50% a year earlier. Management attributed lower gross profit primarily to several lower-margin products with increased processing costs.
At March 31, 2023, total assets were $53.357 million, total liabilities $37.037 million, and stockholders’ equity $16.320 million. Working capital was $17.968 million. Total debt and related-party notes, including finance leases and financed-asset loans, were $25.652 million; $14.450 million was classified as current. The Webster Bank revolving loan and term loan totaled approximately $19.152 million. Related-party notes payable were $6.162 million.
Material changes and operating indicators
- Sales rose 4.0%, but gross profit fell 9.5% and the gross margin declined 2.2 percentage points.
- Military sales were $10.032 million, down from $10.659 million; commercial sales increased to $2.517 million from $1.403 million.
- Accounts receivable declined to $7.273 million from $9.483 million at year-end, while inventory increased to $32.444 million from $31.821 million.
- Backlog was approximately $72.2 million at March 31. The company expected to recognize about $40.3 million from it in April–December 2023 and $31.9 million in January–September 2024, assuming timely supplier deliveries and customer acceptance.
- Four customers accounted for 57.1% of Q1 sales. The largest customer represented 24.3%.
Outlook, risks, and notable matters
- Management expected 2023 sales to be comparable to 2022 and believed operating cash flows and backlog would support short-term liquidity needs. This is management’s expectation, not a quantified formal earnings forecast.
- The company was out of compliance with a Webster Bank fixed-charge coverage covenant at March 31. On August 4, 2023, the bank waived the resulting default and temporarily reduced the required ratio to 0.95:1.00 for the quarters ending June 30 and September 30, 2023. The facility is secured by substantially all company assets and matures in December 2025.
- Management cited exposure to higher interest rates, inflation, skilled-labor availability, volatile or disrupted raw-material supply (including titanium), sole-source suppliers, defense-budget changes, and customer concentration.
- A pending Contract Pharmacal dispute seeks $700,000 in damages; the company disputes the claim and intends to contest it. The appeal was pending, with no argument date set in the filing.
- Management concluded internal controls over financial reporting were not effective at March 31, 2023. Previously identified material weaknesses—in IT system design and management review controls for inventory reserves and income-tax provisions—had not been remediated.
- The company disclosed that its Q1 10-Q was filed late and that NYSE American had issued a notice of noncompliance with timely-filing standards. The company stated that filing the report would cure the delinquency.
Key facts for investors to verify
- Whether AIRI met the amended Webster covenant requirements in subsequent quarters and how the amendment affects borrowing availability and debt service.
- Whether backlog converts to revenue on schedule, particularly given supplier, processing, and customer-acceptance assumptions.
- Whether gross margins recover despite higher processing and financing costs, and whether management’s comparable-sales expectation is achieved.
- Progress in remediating the disclosed internal-control material weaknesses.
- Developments in the Contract Pharmacal appeal and any resulting financial exposure.